Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALORA vs LOPURIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
LOPURIN is a brand name for allopurinol, a xanthine oxidase inhibitor. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prostate cancer (palliative),Breast cancer (palliative, in selected cases),Postpartum breast engorgement (prevention)
Gout prophylaxis,Management of hyperuricemia in patients with cancer undergoing chemotherapy,Prevention of recurrent calcium oxalate calculi in patients with hyperuricuria
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
200-600 mg orally once daily, typically starting at 300 mg/day and adjusting based on serum urate levels.
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (renal function dependent). Accumulation in renal failure; half-life of oxypurinol may exceed 100 hours in ESRD.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates).
Primarily hepatic via aldehyde oxidase to oxypurinol (alloxanthine), which is also active; minor metabolism by xanthine oxidase.
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
Renal (primarily as unchanged drug and active metabolite oxypurinol): ~70% urinary excretion; remainder biliary/fecal. Dose adjustment required in renal impairment.
Estradiol is approximately 97-99% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. The binding to SHBG is high affinity, while albumin binding is nonspecific and lower affinity.
Allopurinol: <1%; oxypurinol: ~20% (primarily to albumin). Negligible displacement interactions.
The apparent volume of distribution (Vd) of estradiol is approximately 5-10 L/kg, indicating extensive distribution into tissues including breast, adipose, and reproductive organs. This large Vd reflects sequestration in adipose tissue and other estrogen-sensitive tissues.
Allopurinol: ~1.6 L/kg; oxypurinol: ~0.6 L/kg. Indicates extensive tissue distribution, including renal and hepatic tissues.
The bioavailability of estradiol from the transdermal system is approximately 10% compared to oral administration, due to avoidance of first-pass hepatic metabolism. The absolute bioavailability relative to intravenous is near 100%, as transdermal delivery provides direct systemic absorption.
Oral allopurinol: ~80% (mean); conversion to oxypurinol reduces systemic availability of parent drug. Food delays absorption but does not affect extent.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). Not studied in severe impairment (GFR <30 m L/min); use with caution.
For GFR 10-20 m L/min: 200 mg/day; GFR <10 m L/min: 100 mg/day or avoid use; consider alternative in severe impairment.
Contraindicated in severe hepatic disease (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use lowest effective dose and monitor. No adjustment for mild (Child-Pugh class A).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%.
Not approved for use in pediatric patients. Safety and efficacy not established.
Children 6-10 years: 100 mg orally once daily; 11-16 years: 200-300 mg orally once daily; adjust based on serum urate.
Use lowest effective dose and duration. Consider increased risk of cardiovascular events, thromboembolism, and malignancy. Starting dose 0.025 mg/day with gradual titration as needed.
Start at lower end of dosing range (100-200 mg/day) due to age-related renal decline; monitor renal function and urate levels.
Estrogens increase the risk of endometrial cancer. Unopposed estrogen increases the risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures, including endometrial sampling if indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
No FDA black box warning.
Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), probable dementia (increased risk in women ≥65 years), breast cancer, endometrial cancer, gallstones, hypertriglyceridemia, fluid retention, hypocalcemia, hereditary angioedema, and exacerbation of endometriosis.
Hypersensitivity syndrome (DRESS) may occur; discontinue at first sign of rash,Acute gout flares may occur upon initiation; prophylactic colchicine or NSAIDs recommended,Renal impairment requires dose adjustment; increase doses cautiously,Monitor liver function; hepatotoxicity reported,Bone marrow suppression (leukopenia, thrombocytopenia) may occur,Anticoagulant effect of warfarin may be enhanced
Undiagnosed abnormal genital bleeding, known/suspected pregnancy, known/suspected breast cancer (except in selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history of these conditions, active arterial thromboembolic disease, known protein C/protein S/antithrombin deficiency or other thrombophilic disorders, liver dysfunction or disease, known hypersensitivity to estradiol or any component.
Hypersensitivity to allopurinol or any component,Concurrent use with azathioprine or mercaptopurine unless dose reduction is implemented
No significant food interactions. Avoid grapefruit juice if on hormonal therapy as it may increase estrogen levels.
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat). Limit alcohol intake, particularly beer and spirits. Maintain adequate hydration. No significant food-drug interactions reported.
ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in female offspring, as well as congenital anomalies including cardiac defects and limb reduction defects. Second and third trimesters: increased risk of fetal genital abnormalities and potential for long-term reproductive tract effects. Estrogens are not indicated for use during pregnancy.
FDA Pregnancy Category D. First trimester: risk of congenital heart defects, cleft palate, and hypospadias based on animal studies and limited human data. Second and third trimesters: risk of fetal renal dysfunction, oligohydramnios, and neonatal renal impairment due to fetal renin-angiotensin system suppression.
Estradiol is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. ALORA may reduce milk production and quality due to estrogenic effects. Use during breastfeeding is not recommended. If used, monitor the infant for signs of estrogen exposure such as breast enlargement or vaginal bleeding.
Small amounts of LOPURIN are excreted in breast milk. M/P ratio is approximately 0.2. The American Academy of Pediatrics considers the drug compatible with breastfeeding, but caution is advised due to potential for infant renal effects. Monitor infant for hypotension and renal function.
ALORA is contraindicated in pregnancy; no dosing adjustments are applicable. The physiological increase in estrogen-binding proteins and hepatic clearance during pregnancy would theoretically reduce efficacy if used, but use is prohibited due to teratogenicity.
Increased plasma volume during pregnancy may reduce concentrations; dose adjustments are not routinely recommended due to variable pharmacokinetics. However, if blood pressure control is inadequate, consider increasing the dose under close monitoring. Postpartum, reduce dose to prepregnancy level to avoid hypotension.
ALORA 0.03% estradiol vaginal cream is indicated for atrophic vaginitis. Apply 1-2 g daily for 2 weeks, then taper. May cause endometrial hyperplasia if used without progestin in women with intact uterus. Avoid in breast cancer history.
Allopurinol is a xanthine oxidase inhibitor. Initiate at low dose (100 mg/day) and titrate to reduce risk of gout flares. Monitor for hypersensitivity reactions, especially in renal impairment. Doses must be adjusted for renal function (Cr Cl <60 m L/min). Do not use with azathioprine or 6-mercaptopurine without dose reduction of cytotoxic agents. Avoid restarting after severe hypersensitivity.
Use the measured applicator for correct dose.,Apply cream at bedtime for best absorption.,Wash applicator after each use with soap and water.,Report any abnormal vaginal bleeding immediately.,Do not use if allergic to estrogens.
Take after meals to reduce GI upset.,Drink plenty of fluids (2-3 liters/day) to prevent kidney stones.,Report any rash, itching, or swelling immediately as these may signal a serious allergic reaction.,Do not stop medication abruptly; gout flares may occur during early treatment.,Avoid alcohol, especially beer, as it can increase uric acid levels.,Keep regular appointments for blood tests to monitor uric acid and kidney function.
No interactions on record
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"The combination of allopurinol and captopril increases the risk of hypersensitivity reactions, including Stevens-Johnson syndrome and angioedema, due to a pharmacodynamic interaction that potentiates immune-mediated adverse effects. This is particularly concerning in patients with renal impairment, where both drugs may accumulate, and can lead to severe cutaneous adverse reactions or hematologic toxicities."
"Allopurinol inhibits xanthine oxidase, an enzyme involved in the catabolism of purine analogs. Tegafur is a prodrug of 5-fluorouracil and is metabolized via the same pathway. Coadministration of allopurinol may reduce the conversion of tegafur to its active metabolite, thereby decreasing the therapeutic efficacy of tegafur. This can lead to suboptimal antineoplastic effect and potential treatment failure."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALORA vs LOPURIN, answered by our medical review team.
ALORA is a Estrogen that works by Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.. LOPURIN is a Xanthine oxidase inhibitor that works by LOPURIN is a brand name for allopurinol, a xanthine oxidase inhibitor. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALORA and LOPURIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALORA is: Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.. The standard adult dose of LOPURIN is: 200-600 mg orally once daily, typically starting at 300 mg/day and adjusting based on serum urate levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALORA and LOPURIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALORA is classified as Category C. ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in fe. LOPURIN is classified as Category C. FDA Pregnancy Category D. First trimester: risk of congenital heart defects, cleft palate, and hypospadias based on animal studies and limited human data. Second and third trimeste. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.